

The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact.

Title: The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact.

Publication year: 2021

Journal: British journal of haematology

Authors: Department of Haematology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, Hampshire, UK.

Society: National Institute for Health and Care Excellence

Origin country: United Kingdom

Target countries: United Kingdom

DOI: 10.1111/bjh.17280

PMID: 33474730

Source: <https://pubmed.ncbi.nlm.nih.gov/33474730/>

Br J Haematol Br J Haematol 3812 phebblackwell 0372544 BJH British Journal of Haematology 0007-1048 1365-2141 pmc-is-collection-domain yes pmc-collection-title Wiley - PMC COVID-19 Collection PMC7898641 PMC7898641.2 7898641 8013564 33474730 10.1111/bjh.17280 BJH17280 2 Covid■19 Covid■19 The NICE COVID■19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact Orchard Kim 1 * Dignan Fiona L. 2 * Lee Julia 3 Pearce Rachel 3 Desai Monica 4 McFarlane Emma 4 Parkin Angela 4 Shearn Peter 4 Snowden John A. <https://orcid.org/0000-0001-6819-3476> 5 6 john.snowden1@nhs.net 1 Department of Haematology University Hospital Southampton NHS Foundation Trust Tremona Road Southampton Hampshire UK 2 Department of Clinical Haematology Manchester University NHS Foundation Trust Manchester UK 3 BSBMTCT Registry Guy's and St. Thomas' NHS Foundation Trust London UK 4 National Institute for Health and Care Excellence Manchester UK 5 Department of Haematology Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital Sheffield UK 6 Department of Oncology & Metabolism University of Sheffield Sheffield UK * Correspondence: Professor John A. Snowden, Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield S10 3LX, UK. Email: john.snowden1@nhs.net * Joint first author.

20 1 2021 2 2021 192 3 378693 10.1111/bjh.v192.3 467 473 10 10 2020 24 11 2020 01 04 2021 03 03 2021 18 02 2026 7898641 10.1111/bjh.17280 1 20 01 2021 8013564 10.1111/bjh.17280 2 20 01 2021 © 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd <https://creativecommons.org/licenses/by-nc-nd/4.0/> This is an open access article under the terms of the <http://creativecommons.org/licenses/by-nc-nd/4.0/> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non■commercial and no modifications or adaptations are made. haematopoietic stem cell transplantation autologous allogeneic COVID■19 SARS■CoV■2 donor British Society of Blood and Marrow Transplantation and Cellular Therapy N/A National Institute for Health and Care Excellence 10.13039/100010377 N/A pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY-NC-ND source-schema-version-number 2.0 cover-date February 2021 details-of-publishers-converter Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.1 mode:remove_FC converted:01.04.2021 A new coronavirus SARS■CoV■2 emerged at the start of 2020 with rapid worldwide spread. It is the causative agent of Coronavirus Disease 2019 (COVID■19). The resulting pandemic has been

challenging for centres undertaking autologous and allogeneic haematopoietic stem cell transplants (HSCT). One of the main risks in HSCT is infection susceptibility, including viral infections, which are often more severe and life-threatening. 1

In response to the COVID-19 pandemic, the National Institute for Health and Care Excellence (NICE) published the first version of the COVID-19 rapid guideline for HSCT (NG164) on 1 April 2020 2 ; this was updated on 29 July 2020 in response to the changing context of the pandemic. The British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) and the European Society for Blood and Marrow Transplantation (EBMT) also developed detailed guidance to support transplant centres. 3 , 4 , 5

This paper describes the development and update processes for NICE NG164, detailing the rationale behind the recommendations, implementation and the impact of COVID-19 on HSCT activity in the UK compared with 2019, based on registrations in the BSBMTCT registry. The full NICE guidance can be obtained from: <https://www.nice.org.uk/guidance/ng164> .

NICE NG164 was developed jointly by NICE and NHS England and NHS Improvement (NHSE&I) in March 2020. The main stages of development included scoping, appointing an independent advisory expert panel, conducting evidence reviews, drafting recommendations, as well as targeted peer review through stakeholder consultation. The cross-speciality independent clinical advisory panel for HSCT included experts from the BSBMTCT, the NHSE&I Clinical Reference Group (CRG) for Blood and Marrow Transplantation (BMT), supported by the NICE guideline development team.

The clinical review considered how the delivery of HSCT services should be managed for patients and donors during the COVID-19 pandemic and how to mitigate risks of COVID-19, at all stages of HSCT. An initial literature search was undertaken on 24 March 2020, in the early days of the pandemic when little information was available on COVID-19. A targeted approach was taken to identify published and preprint guidance and evidence. The recommendations were informed by a combination of evidence and expert panel consensus. The final guideline scope and equality impact assessment and the interim process and methods manual are published on the NICE website. 6 An update of the NICE guideline was published, incorporating advice based on emerging evidence on the SARS-CoV-2 virus, the epidemiology and clinical impact. 7 A surveillance approach was implemented following publication involving frequent searches of literature and guidance, and a pragmatic intelligence gathering approach to identify other information which could impact on recommendations, such as changing COVID-19 alert levels and implementation feedback.

Patients undergoing HSCT experience significant anxiety and distress. 8 The Shielding Behavioural Survey undertaken by the Office for National Statistics (ONS) in June 2020 showed that 35% of people who are clinically extremely vulnerable reported that their mental health had become slightly worse (29%) or much worse (6%). 9 A survey undertaken by Anthony Nolan, using the same wording as the ONS survey, showed that 79/139 (57%) of respondents reported that their mental health had become slightly worse (57/139, 41%) or much worse (22/139, 16%) as a result of the coronavirus pandemic (Anthony Nolan, personal communication).

To support their mental wellbeing, the guideline recommends signposting of patients and families to charities and support groups. Documented examples include a local transplant teams support telephone line established during the pandemic by Anthony Nolan. 10

NG164 recommends measures to mitigate risks of nosocomial transmission, including telephone or video consultations, avoiding non-essential clinic visits, coordinating blood tests and using alternative means of delivering medications. Many of these measures had been successfully implemented in centres across the UK. 11 Additionally, transplant centre healthcare workers are advised to follow UK guidance on infection prevention and control which includes the use of personal protective equipment (PPE) and recommendations on patient transfers, transport and options for outpatient settings. 12

Patients undergoing HSCT are immunocompromised and may have atypical presentations of SARS-CoV-2 infection. 13 They are also susceptible to other post-transplant complications which may have similar symptoms to COVID-19, including neutropenic sepsis or pneumonia caused by other pathogens. The expert panel was concerned that patients who feel unwell may be advised to isolate at home, which means that other types of infection or neutropenic sepsis which is immediately life-threatening could be missed. Consequently, the guideline recommends that patients with new symptoms suggestive of COVID-19 contact their transplant centre rather than the national NHS emergency telephone number, in order to receive specialist advice. The guidance also aligns with existing NICE guidance for people with cancer and suspected neutropenic sepsis, recommending assessment in secondary or tertiary care and offering immediate empirical antibiotic therapy (NICE CG151 14).

Patients with symptoms suggestive of COVID-19 require testing for SARS-CoV-2 . Isolation and the use of PPE are required until the test result is known. 15 If a patient tests positive for SARS-CoV-2, NG164 recommends following UK guidance on the management of exposed healthcare workers and patients in hospital settings, which includes information on testing and isolating patients. 15

Transplant recipients are susceptible to viral infections, and evidence shows that respiratory viral infections can increase transplant-related mortality. 1 Recent evidence also suggests that this is true for HSCT patients who develop a SARS-CoV-2 infection, 16 , 17 , 18 , 19 and advice includes social distancing, regular hand washing and self-isolation for the 14 days prior to admission. Patients should also be tested for SARS-CoV-2 prior to admission regardless of whether they have symptoms, due to the high rate of asymptomatic carriers of the virus (reviewed in Ref. 20).

If patients have been in close contact with an individual infected with COVID-19 within the preceding week, deferral of transplant by three weeks was recommended. This recommendation was in line with EBMT guidance at that time, but since then the interval has been reduced to 'a minimum of 14 days' by the EBMT before the start of any transplant-related procedures and could be subject to further change. 3 , 5

In patients with high-risk haematological disease progression, morbidity or mortality who test positive for SARS-CoV-2 , it is recommended that transplant is deferred until they are asymptomatic and have three negative polymerase chain reaction (PCR) tests taken at least one week apart, similar to EBMT guidance which recommends two negative swabs, a deferral of 14 days from the first negative swab and a repeated swab prior to the start of conditioning. 3 In patients with lower risk disease it is suggested that their transplant is delayed by three months. A repeat assessment of organ function including a chest X-ray, echocardiogram and pulmonary function tests is recommended as organ function may have deteriorated due to the SARS-CoV-2 infection.

Following the initial rapid spread of SARS-CoV-2 , the peak of infection in the general population occurred in mid-April 2020 21 with COVID-19 deaths peaking soon afterwards. Measures were required to reduce the risk and to mitigate the potential interruption to a planned transplant. For example, transplant centres and donor registries advised donors to follow government guidance on strict social distancing behaviour for at least four weeks before donating. Donors were advised to keep in contact with the harvest centre and to seek advice if they developed any symptoms suggestive of COVID-19. Due to the reported asymptomatic carriage of the virus by individuals, which ranges from 18%–88% depending upon the population studied, 22 , 23 screening by throat and nasal swabs for SARS-CoV-2 PCR at least once prior to donation and ideally on the day of donation was recommended. Screening on the day of donation was intended to provide an audit trail rather than inform the use of the harvested stem cells. In theory it was possible that a donor would be asymptomatic but positive for COVID-19 on the day of donation. There have been reports of SARS-CoV-2 RNA being detected in several organs and in blood; 24 however, the presence of the potentially infectious virus in blood, and hence blood products, in an asymptomatic

donor is remote. 25 , 26 The swab test on the day of donation would allow tracing in the event that a transplant recipient became unwell with COVID-19 post-transplant. Similarly, donors were asked to inform harvest teams if they developed any COVID-19 symptoms within two weeks of donation. 27

A major change in the allogeneic transplant procedure was a recommendation by some donor registries to cryopreserve stem cells prior to the start of conditioning for the recipient, based on BSBMTCT recommendations and expert consensus. 3 , 4 , 27 , 28 The intention of this recommendation was to avoid the possibility that a donor was unable to donate due to developing COVID-19. Evidence from two retrospective studies indicated that the use of cryopreserved stem cells in allogeneic transplantation had no impact on transplant outcome. 29 , 30 If fresh cells were to be used, it was recommended that an alternative donor, including for haplo-identical or cord blood, was identified in case the selected donor was unable to donate.

Donors who had tested positive for COVID-19, even if asymptomatic, were required to be deferred for three months after the resolution of symptoms. This is longer than the period of 28 days recommended by the EBMT 3 , 5 , but with evidence of long-term medical complications following COVID-19 the longer period of deferral seemed appropriate. However, it was recognised that in situations where the clinical urgency of the transplant was high then earlier donation would be possible with a risk assessment, an asymptomatic period and repeated negative swabs for SARS-CoV-2 prior to donation.

Based on the increased risk of mortality from other respiratory viruses 31 , it was highly probable that transplant recipients would be at increased risk of mortality from SARS-CoV-2. Emerging evidence supports this assumption with data from the EBMT COVID-19 survey reporting the outcome of confirmed COVID-19 infection in 272 patients, 175 allogeneic SCT and 97 autologous SCT. The mortality rate was 30% in allogeneic recipients and 25.3% in autologous recipients. 17 A smaller report in 25 patients with haematological malignancies reported a mortality rate of 40% but only seven HSCT recipients were included in this study. 32 The CIBMTR registry has a cumulative reporting process and by the end of September 2020 a total of 554 cases of COVID-19 had been reported, with a mortality rate of 19.1%. 33 As with subgroups of patients with haematological malignancies, similar high mortality rates in HSCT recipients have been reported. 18 , 19 Strict social distancing behaviour was recommended in line with current guidelines. 3 , 4 , 12

Depletion of experienced transplant teams was acknowledged with staff remaining away from work, either due to symptomatic infection, contact with proven cases, or personal reasons. 12 The risk of nosocomial infection from staff was of great concern 34 ; in the report by Malard, a large number of infections in patients with haematological malignancies were thought to have been acquired in hospital. 32 It was therefore important to ensure that transplant programmes could provide 'COVID-19 safe' environments with a key component being education of staff on the symptoms of COVID-19, regular symptom checks and routine screening of asymptomatic staff whenever possible. During the preparation of the guideline it was clear that there was uncertainty regarding the period that an individual may remain potentially infective, with reports of prolonged positivity by PCR despite resolution of symptoms. 24 , 35 Return to work recommendations from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control (ECDC) and EBMT indicated that staff should be asymptomatic, fever being the main symptom to have been resolved, have a minimum time-period since onset of symptoms and ideally two negative swabs for SARS-CoV-2 .

The approach by the NICE guidelines group was pragmatic, acknowledging the rapidly changing evidence and limitations of testing. 36 , 37 , 38 , 39 , 40 Rivett et al . reported the results of a screening programme for asymptomatic staff in a large teaching hospital in the UK, 41 indicating that the presence or absence of symptoms alone would miss individuals still potentially shedding virus. Similar to the 'test-based strategy' of the CDC, 42 a recommendation was made for staff to be asymptomatic for at least seven days plus a negative SARS-CoV-2 swab PCR test prior to returning to direct contact with transplant recipients.

The creation of 'COVID-19 safe' environments for transplant recipients was based on the provision of regular swab testing of staff. As of September 2020, PCR testing for SARS-CoV-2 was limited and routine testing of asymptomatic staff was not achieved in all sites despite the NICE recommendation. A BSBMTCT survey of the 53 transplant units in the UK conducted in September 2020 received 42 responses; of these only 24 (57%) of centres were offering routine testing of asymptomatic staff with the majority (83%) using nose and throat swab tests for SARS-CoV-2 (Bloor et al., BJH 2020 accepted).

Given the uncertainties during the early phase of the COVID pandemic, there was a need to prioritise HSCT procedures depending on risk of disease indication if untreated by HSCT, and potential risk of severe COVID-19 infection during and after HSCT. To inform shared decision-making with patients, NICE recommended that multidisciplinary teams (MDTs) consider using transplant outcome predictive tools such as the haematopoietic cell transplantation-specific comorbidity index (HCT-CI) 43, 44 or the refined disease risk index (DRI), 45 but also to be aware of the limitations of these tools. Prioritising treatment for people with high risk of haematological disease progression, morbidity or mortality enabled units to focus on critically urgent, curative HSCT procedures concentrated in larger units where COVID-19 minimised pathways could be provided. Close liaison within local MDTs was recommended to consider suitable alternative treatments if the risks associated with COVID-19 were felt to be higher than the risk of continuing with the transplant.

NICE recommended different ways of working within HSCT programmes, as well as regional (adults) and national (paediatrics) via 'clusters' of HSCT centres within operational delivery networks (ODNs) to provide a 'safety net' should any programmes fail to maintain quality standards and/or meet demands in activity. ODNs were extended to support devolved nations. Modifications to haematopoietic stem cell collection (apheresis and bone marrow harvest) practice and facilities were also recommended. Engagement between stakeholders was critical, 3, 5, 27, 46, 47 along with reporting into the EBMT registry experience. 17

Table I and Fig 1A,B summarise the autologous and allogeneic HSCT activity (adult and paediatric combined) as reported to the BSBMTCT registry during the period 1 Jan–31 July in 2019 and 2020. Both autologous and allogeneic HSCT activity fell in March 2020, reaching a nadir in April 2020, which corresponded with the peak of the COVID-19 crisis in the UK. Autologous HSCT was reduced to a greater extent than allogeneic HSCT, reaching 16.4% of the 2019 activity, while allogeneic HSCT fell to 65%.

Day 0 transplant registrations received by the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) Registry for the period 1 January–31 July in 2019 compared with 2020. The numbers include adult and paediatric transplant activity.

John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. Fig 1 (A) Day 0 reported autologous HSCT activity in the period 1 January–31 July, comparing monthly totals for 2019 and 2020. P values were determined from a linear regression model using monthly data for 2007–2019, assuming normally distributed variation. (B) Day 0 reported allogeneic HSCT activity in the period 1 January–31 July, comparing monthly totals for 2019 and 2020. P values were determined from a linear regression model using monthly data for 2007–2019, assuming normally distributed variation. [Colour figure can be viewed at wileyonlinelibrary.com]

These data show the total transplant activity in the UK but there was considerable heterogeneity of the impact around the country; some small autologous HSCT units ceased all activity, and some large programmes reduced autologous HSCT activity but maintained allogeneic activity close to

2019 levels, while some large programmes reduced both (BSBMTCT registry data). The impact of the COVID-19 crisis on individual centres was influenced by several factors, including local infection rates, staffing levels and risk assessments. The reduction of transplant activity, particularly for autologous HSCT, created a large 'backlog' of patients awaiting transplantation, and, by the time of the second wave of the pandemic, HSCT in the UK was still in recovery phase as activity had still not reached that of 2019.

The COVID-19 pandemic has posed an exceptional challenge for the stem cell transplant community which responded quickly by publishing relevant guidance for the management of transplant recipients, advice on safe service delivery and donor issues⁴, and was updated in response to new evidence and government advice. The advice and experience from experts within EBMT was invaluable in formulating these guidelines.³ The NHS also responded quickly to the complex issues posed by the pandemic to support patients, NHS trusts, clinicians and commissioners. The guidelines will require ongoing review as more clinical evidence emerges and government advice changes to address further 'waves' of the pandemic, and, ultimately, the challenge of 'endemic' COVID-19.

JAS was chair of BMT-UK CRG from June 2016–June 2020, and FLD is chair from April 2020. They co-chaired the BMT-UK CRG from April–June 2020. KO was President of BSBMTCT from January 2018 to December 2020, and JS is President from January 2021–December 2022. No other conflicts of interest were declared.

All the authors actively contributed as per ICMJE authorship requirements. NICE NG164 was developed, published (1 April 2020) and updated (29 July 2020) by EM, MD, AP and PS, with clinical input led by JAS, KO and FLD on behalf of NHSE&I Clinical Reference Group (CRG) for Blood and Marrow Transplantation and BSBMTCT. The BSBMTCT Head of Registry and Statistician (JL & RP) provided data, statistical analysis and interpretation of the registry data, with clinical input from KO, JAS and FD. All authors wrote, reviewed and approved the manuscript.

NICE NG164 was produced by NICE as part of the response of NHSE&I to the COVID-19 pandemic. JAS and FLD receive remuneration from NHSE&I for chairing the CRG. BSBMTCT maintains the national registry with data management and statistical support (JL and RP). All patients have consented for data entry into the registry in accordance with data protection regulations.

The authors wish to thank the executive committee of the BSBMTCT for their contribution to these guidelines: Deborah Richardson, Dominic Culligan, Kavita Raj, Maria Gilleece, Eduardo Olavarria, Marie Waller, Bim Laguda, Rachael Hough, Ram Malladi, Jennifer Byrne, Matthew Collin, Stephen Robinson. The authors would also like to thank the UK and Ireland Paediatric BMT Group (chair, Persis Amrolia), UK Myeloma Forum (John Ashcroft and Gordon Cook) and other stakeholder groups who contributed to development and updating of NG164.

The authors also wish to thank Janette Harper and Rob Coster from NHSE&I for their contribution to these guidelines and all members of the NHSE&I Clinical Reference Group for Blood and Marrow Transplantation, and Henny Braund, Amelia Chong, Rob Danby and members of the Anthony Nolan team, who have supported regular video-conferenced discussions throughout the pandemic.